NEW YORK (GenomeWeb) – Contract manufacturing firm Aldevron announced today that it has agreed to collaborate with non-profit foundation Myeloma Crowd to advance treatments and attempt to find a cure for multiple myeloma.

Aldevron has licensed minicircle DNA technology developed by Stanford University professor Mark Kay. Minicircles are small circular plasmid derivatives that are free of all prokaryotic vector parts. They have been used in research as transgene carriers for the genetic modification of mammalian cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

Sponsored by

In these times of economic constraint and increasing research costs, shared resource cores have become a cost-effective and essential platform for researchers who seek to investigate complex translational research questions.